Investors Are Watching: Xilinx Inc. (NASDAQ:XLNX), Linn Energy, LLC (NASDAQ:LINE), SanDisk Corp. (NASDAQ:SNDK), Cyclacel Pharmaceuticals(NASDAQ:CYCC), TriMas Corporation (NASDAQ:TRS)


Xilinx, Inc. (NASDAQ:XLNX) on 16 October announced second quarter fiscal 2015 sales of $604 million, down 1% from the prior quarter and up 1% from the same quarter of the prior fiscal year. Second quarter fiscal 2015 net income was $172 million or $0.62 per diluted share. Xilinx Inc. (NASDAQ:XLNX) in last trading activity moved up 6.65% to close at $41.05. Company weekly performance is 11.46% while its quarterly performance stands at -15.06%. Xilinx Inc. (NASDAQ:XLNX) is -26.16% away from its 52 week high.

LINN Energy, LLC (NASDAQ:LINE) and LinnCo, LLC announced that management will host a conference call on Tuesday, November 4, 2014, at 10 a.m. On last trading day Linn Energy, LLC (NASDAQ:LINE) moved up 2.78% to close at $24.77. Its volatility for the week is 10.68% while volatility for the month is 5.62%. LINE’s sales growth for past 5 years was 10.20% and its EPS growth for past 5 years was -19.20%. Linn Energy, LLC (NASDAQ:LINE) monthly performance is -20.02%.

SanDisk Corporation (NASDAQ:SNDK) declared a fourth quarter 2014 cash dividend of 30 cents per share on the company’s common stock. The dividend will be payable on November 24, 2014 to stockholders of record at the close of business on November 3, 2014. On last trading day SanDisk Corp. (NASDAQ:SNDK) fell -2.94% to close at $82.80. Its volatility for the week is 5.16% while volatility for the month is 3.50%. SNDK’s sales growth for past 5 years was 13.00% and its EPS growth for past 5 years was 20.00%. SanDisk Corp. (NASDAQ:SNDK) monthly performance is -19.78%.

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) on 9 October announced that the independent Data and Safety Monitoring Board or DSMB for the Company’s Phase 3 SEAMLESS study in acute myeloid leukemia or AML has completed its fourth planned safety review and recommended that the study should continue as planned without any modifications. Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) has 8.58% insider ownership while its institutional ownership stands at 8.30%. In last trading activity company’s stock closed at $3.21.

Stock analysts at William Blair began coverage on shares of TriMas Corporation (NASDAQ:TRS) in a report issued on Thursday, TheFlyOnTheWall.com reports. The firm set a “market perform” rating and a $26.00 price target on the stock. William Blair’s target price suggests a potential downside of 3.31% from the stock’s previous close. On Friday shares of TriMas Corporation (NASDAQ:TRS) closed at $26.54. Company’s sales growth for last 5 years was 6.60% and EPS growth for next 5 years is recorded as 11.00%.


Leave a Reply

Your email address will not be published. Required fields are marked *